Pruthi RS - Search Results

1

Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype.

Kardos J, Wobker SE, Woods ME, Nielsen ME, Smith AB, Wallen EM, Pruthi RS, Hayward MC, McGinty KA, Grilley-Olson JE, Patel NM, Weck KE, Black P, Parker JS, Milowsky MI, Hayes DN, Kim WY. Kardos J, et al. Among authors: pruthi rs. JCO Precis Oncol. 2017 Jul 6;1:PO.17.00027. doi: 10.1200/PO.17.00027. eCollection 2017. JCO Precis Oncol. 2017. PMID: 32913973 Free PMC article.

2

Partial nephrectomy with fibrin glue repair: measurement of vascular and pelvicaliceal hydrodynamic bond integrity in a live and abbatoir porcine model.

Kouba E, Tornehl C, Lavelle J, Wallen E, Pruthi RS. Kouba E, et al. Among authors: pruthi rs. J Urol. 2004 Jul;172(1):326-30. doi: 10.1097/01.ju.0000123823.27846.d7. J Urol. 2004. PMID: 15201805

3

Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer.

Pruthi RS, Derksen E, Gaston K, Wallen EM. Pruthi RS, et al. Urology. 2004 Oct;64(4):637-42. doi: 10.1016/j.urology.2004.04.047. Urology. 2004. PMID: 15491687 Review. No abstract available.

4

Impact of race, age, income, and residence on prostate cancer knowledge, screening behavior, and health maintenance in siblings of patients with prostate cancer.

Pruthi RS, Tornehl C, Gaston K, Lee K, Moore D, Carson CC, Wallen EM. Pruthi RS, et al. Eur Urol. 2006 Jul;50(1):64-9. doi: 10.1016/j.eururo.2005.09.024. Epub 2005 Dec 12. Eur Urol. 2006. PMID: 16364537

5

Cyclooxygenase-2: a therapeutic target for prostate cancer.

Pruthi RS, Wallen EM. Pruthi RS, et al. Clin Genitourin Cancer. 2005 Dec;4(3):203-11. doi: 10.3816/CGC.2005.n.034. Clin Genitourin Cancer. 2005. PMID: 16425990 Review.

6

Large presacral schwannoma after radical prostatectomy.

Pruthi RS, Hubbard JS, Kouba E, Funkhouser W, Wallen E. Pruthi RS, et al. Eur Urol. 2006 May;49(5):914-7. doi: 10.1016/j.eururo.2006.01.057. Epub 2006 Feb 24. Eur Urol. 2006. PMID: 16524659

7

Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.

Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E. Pruthi RS, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2172-7. doi: 10.1158/1078-0432.CCR-05-2067. Clin Cancer Res. 2006. PMID: 16609031 Clinical Trial.

8

Virtual pyeloscopy using volumetric depth peeling.

Fielding JR, Borland D, Lee KH, Clarke JP, Wallen E, Pruthi R, Taylor RM. Fielding JR, et al. Acad Radiol. 2006 Jun;13(6):759-63. doi: 10.1016/j.acra.2006.02.042. Acad Radiol. 2006. PMID: 16679279

9

Characterization of biochemical recurrence after radical prostatectomy.

Molitierno J, Evans A, Mohler JL, Wallen E, Moore D, Pruthi RS. Molitierno J, et al. Among authors: pruthi rs. Urol Int. 2006;77(2):130-4. doi: 10.1159/000093906. Urol Int. 2006. PMID: 16888417

10

Cyclooxygenase-2 inhibitors and other NSAIDs in urology: current peril or future promise?

Pruthi RS, Kouba E, Carson CC 3rd, Wallen EM. Pruthi RS, et al. Urology. 2006 Nov;68(5):917-23. doi: 10.1016/j.urology.2006.06.013. Urology. 2006. PMID: 17113880 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters